Trial · NCT06660498
Pomalidomide as an Immune-enhancing Agent for the Control of HIV
NCT06660498, Phase 1, Phase 2, Active not recruiting, University of Aarhus
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pomalidomide as an Immune-enhancing Agent for the Control of HIV. Trials, record NCT06660498. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06660498
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pomalidomide as an Immune-enhancing Agent for the Control of HIV
- NCT number
- NCT06660498
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 32 participants, estimated
- Lead sponsor
- University of Aarhus
- Conditions
- HIV-1 Infection
- Interventions
- Pomalidomide 2 mg, Placebo, Aspirin 75 mg
- First posted
- 2024-10-28
- Last updated
- 2026-05-07
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of treatment, measured as the time from ART cessation until meeting ART restart criteria. | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Primary | Safety of treatment, measured by the number of treatment-emergent adverse events (AEs) of grade 3 or higher that are probably or definitely related to the study treatment. | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | Safety, defined as all other treatment-emerging adverse events (AEs) | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | AEs are graded according to severity and assessed as either not related or possibly, probably or definitely related to study treatment. |
| Secondary | Rebound viral kinetics during the ATI, including plasma HIV-1 RNA copies/mL doubling times | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The proportion of participants maintaining HIV-1 RNA levels below 1,000 copies/mL at the end of the ATI. | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The proportion of participants who have not met ART restart criteria at the end of the ATI. | From ATI to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The frequency of peripheral blood CD4+ T cells containing total and intact HIV-DNA while on suppressive ART | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | HIV-specific CD4+ responses | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | HIV-specific CD8+ T cell responses | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria | |
| Secondary | The proportion of cells containing constitutive and inducible MS HIV-RNA | From enrollment to the end of treatment at visit 18 or 16 weeks after meeting ART restart criteria |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06660498
GET https://conductscience.org/api/trials/v1/NCT06660498/registered